ITIL-306; TILs Modified with a Co-Stimulatory Antigen Receptor (CoStAR) Targeting FOLR1
Time: 3:15 pm
day: Day 2 - Track B - PM
Details:
- CoStAR enhances T-cell effector function and proliferation in an IL-2 independent manner
- CoStAR is not prone to on-target, off-tumour toxicity experienced with CARs
- Currently being evaluated in a phase 1a/1b clinical trial evaluating safety and feasibility; TIL-306-201
